Roche’s Tecentriq plus chemotherapy meets goal in triple-negative breast cancer trial

This article was originally published here

The phase III IMpassion031 study assessing Tecentriq plus chemotherapy (Abraxane, albumin-bound paclitaxel, nab-paclitaxel, followed by doxorubicin and cyclophosphamide) comparison to placebo plus chemotherapy reached its primary endpoint by

The post Roche’s Tecentriq plus chemotherapy meets goal in triple-negative breast cancer trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply